SCHEMBL5748165

SCHEMBL5748165

COc1ccnc(OS(=O)(=O)C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 1/20 0.44
▸ CCR5 P51681 1/20 0.44
▸ CCR8 P51685 1/20 0.44
▸ NOS3 P29474 2/20 0.42
▸ NOS1 P29475 2/20 0.42
▸ NOS2 P35228 2/20 0.42
▸ NFE2L2 Q16236 7/20 0.41
▸ PDE4A P27815 2/20 0.38
▸ PDE4C Q08493 2/20 0.38
▸ PDE4D Q08499 2/20 0.38
▸ PLAU P00749 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HCRTR1 O43613 1/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ PTGS1 P23219 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ LOX P28300 1/20 0.36
▸ LOXL2 Q9Y4K0 1/20 0.36
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31049812 0.81 PDE4A (0.39) CCR1CCR5CCR8NOS3NOS1
SCHEMBL2749231 0.80 NPC1 (0.47) LMNAPTGS2CA1CA2
SCHEMBL23674532 0.79 CA1 (0.39) PDE4APDE4CPDE4DCA1CA2
SCHEMBL2749354 0.79 RAB9A (0.43) PDE4APDE4CPDE4DLMNAPTGS2
SCHEMBL6481315 0.78 PDE4A (0.39) PDE4APDE4CPDE4DLOXL2CA1
SCHEMBL16559590 0.76 NFE2L2 (0.40) NFE2L2LMNAPTGS1PTGS2CA1
SCHEMBL6474640 0.76 CNR2 (0.43) PDE4APDE4CPDE4DLOXL2CA1
SCHEMBL31090281 0.75 PDE4A (0.45) PDE4APDE4CPDE4DPLAUCA1
SCHEMBL451684 0.75 STS (0.47) NFE2L2LMNAPTGS1PTGS2CA1
SCHEMBL8499219 0.75 L3MBTL1 (0.50) PLAULMNAPTGS1PTGS2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060199823-A1 Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands NEUROGEN CORPORATION (US) 2006-09-07 — — US disclosed
EP-1680424-A2 HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS Neurogen Corporation (US) 2006-07-19 — — EP disclosed
EP-1675858-A2 5-ARYL-PYRAZOLO [4,3-D] PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS NEUROGEN CORPORATION (US) 2006-07-05 — — EP disclosed
US-20050113379-A1 Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands AVENTIS PHARMACEUTICALS, INC. 2005-05-26 — — US disclosed
US-20050070542-A1 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds NEUROGEN CORPORATION 2005-03-31 — — US disclosed
WO-2005028480-A2 5-ARYL-PYRAZOLO[4,3-D]PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS NEUROGEN CORPORATION (US) 2005-03-31 — — WO disclosed
WO-2005023806-A2 HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2005-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070542-A1 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds CRHR1, HTR5A, HTR1D CCR1 222/4885CCR5 203/4885CCR8 953/4885
US-20060199823-A1 Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands CRHR1, CRHR2, HTR5A CCR1 293/4885CCR5 215/4885CCR8 1668/4885
US-20050113379-A1 Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands CRHR1, CRHR2, HTR5A CCR1 293/4885CCR5 215/4885CCR8 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback